Nonpegylated liposomal doxorubicin (Myocet (TM)) combination (R-COMP) chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL): results from the phase II EUR018 trial

作者：Luminari S; Montanini A; Caballero D; Bologna S; Notter M; Dyer M J S; Chiappella A; Briones J; Petrini M; Barbato A; Kayitalire L; Federico M^*

来源：Annals of Oncology, 2010, 21(7): 1492-1499.

DOI：10.1093/annonc/mdp544

• cardiac toxicity
• diffuse large B-cell lymphoma
• elderly patients
• non-Hodgkin's lymphoma
• nonpegylated liposomal doxorubicin

Patients and methods: Seventy-five elderly patients with diffuse large B-cell lymphoma (DLBCL) were studied. Only patients with left ventricular ejection fraction (LVEF) >= 50% were allowed. R-COMP regimen was administered every 3 weeks for three cycles, followed by additional five cycles in case of complete response (CR) or partial response.
Results: From November 2002 to April 2005, 75 patients were registered, of which 72 were evaluated. Median age was 72 years (range 61-83); 56% of patients had high or high-intermediate International Prognostic Index score. Median LVEF at baseline was 61%. Thirty-eight patients had history of abnormal cardiovascular conditions. The overall response rate was 71%, with a CR rate of 57%. After a median follow-up of 33 months, the 3-year overall survival, failure-free survival, and progression-free survival rates were 72%, 39%, and 69%, respectively. Neutropenia (54%) was the most frequent grade 3-4 adverse event (AE); 21% of patients experienced cardiac AEs, graded as 3-4 in 4% of the cases.
Conclusion: R-COMP is an effective regimen for the treatment of DLBCL in elderly patients, with an acceptable tolerability profile.

• 出版日期2010-7